1. Home
  2. ADAG vs LAW Comparison

ADAG vs LAW Comparison

Compare ADAG & LAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$3.28

Market Cap

260.3M

Sector

Health Care

ML Signal

HOLD

Logo CS Disco Inc.

LAW

CS Disco Inc.

HOLD

Current Price

$4.11

Market Cap

220.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADAG
LAW
Founded
2011
2013
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
260.3M
220.0M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
ADAG
LAW
Price
$3.28
$4.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$8.25
$8.00
AVG Volume (30 Days)
203.3K
199.4K
Earning Date
04-01-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
22.58
EPS
N/A
N/A
Revenue
N/A
$156,849,000.00
Revenue This Year
N/A
$11.23
Revenue Next Year
N/A
$10.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.29
52 Week Low
$1.44
$2.45
52 Week High
$4.85
$9.11

Technical Indicators

Market Signals
Indicator
ADAG
LAW
Relative Strength Index (RSI) 35.03 47.33
Support Level $3.18 $4.01
Resistance Level $3.53 $4.52
Average True Range (ATR) 0.23 0.17
MACD -0.06 -0.04
Stochastic Oscillator 9.84 27.66

Price Performance

Historical Comparison
ADAG
LAW

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

About LAW CS Disco Inc.

CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.

Share on Social Networks: